ARTICLE | Product Development
AACR abstracts highlight CDK2 inhibition as solution to CDK4/6 resistance and route to reaching more cancer types
By Lauren Martz, Executive Director, Biopharma Intelligence
April 18, 2024 10:38 PM UTC


CDK4/6 inhibitors have cemented their role as practice-changing drugs for hormone receptor-positive, HER2-negative breast cancer, but resistance — both pre-existing and emergent — has always been a problem. With advances in medicinal chemistry and new modalities offering inroads into challenging targets, companies are turning to selective CDK inhibitors to overcome the problem.
At the American Association of Cancer Research (AACR) Annual Meeting this month, AstraZeneca plc (LSE:AZN; NYSE:AZN) and NiKang Therapeutics Inc. each unveiled preclinical data for CDK2 inhibitors that have advanced into Phase I trials. At least three other companies presented preclinical research on previously disclosed therapies in the emerging drug class. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652079/cdk2-inhibitors-at-aacr-an-answer-to-cdk4-6-resistance